Tarius SAC Tracker®
Briefing Summary: US FDA Posts Advisory Committee Materials About Results of the CV Outcomes Trials for Saxagliptin and Alogliptin – APR 14, 2015 (EMDAC)
The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.
The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held.
To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.
METADATA: Sponsor: AstraZeneca; Takeda Drug Name: saxagliptin; saxagliptin and metformin HCl extended-release; alogliptin; alogliptin and pioglitazone; alogliptin and metformin Drug Class: dipeptidyl peptidase-4 (DPP4) inhibitors Indication: Type 2 diabetes mellitus